2020
Patient Impact
(Patient counts are estimates derived from multiple data sources; results exclude Upjohn)
~86 million
people were immunized by our vaccines
~58 million
people were treated for cardiovascular and metabolic conditions
~2.5 million
people used our smoking cessation treatments
~4.4 million
people were treated with our cancer therapies
~80 million
patients were treated for pain
~28 million
patients were treated with anti-infectives
~1 million
patients were treated for inflammatory disease
~12,400
patients were treated for rare diseases
2020 Global Footprint
(As of December 31, 2020)
~78,500
employees
> 125
countries where Pfizer sells product
43
manufacturing sites (Algiers site transfer to
Viatris delayed until H1 2021)
2020 Pipeline Advancements
(BNT162b2, which is based on BioNTech’s proprietary mRNA technology, was developed by both BioNTech and Pfizer, and the marketing authorization holder is BioNTech in the United States, Europe, U.K., Canada, and other countries.)
7
product approvals (2 key approvals/5 second market approvals)
> 50
Emergency Use Authorizations/Conditional Authorizations/Temporary Authorizations for the Pfizer-BioNTech COVID-19 vaccine, BNT162b2
7
regulatory submissions
32
pipeline assets advanced
CREATING SHAREHOLDER VALUE in 2020
$41.9 billion
in revenue
$8.4 billion
returned to shareholders through cash dividends
$9.4 billion
invested in research & development
Being a Responsible Corporate Citizen in 2020
(The Pfizer Foundation is a charitable organization established by Pfizer Inc. It is a separate legal entity from Pfizer Inc. with distinct legal restrictions.)
$40 million
Committed $40 million in medical and charitable cash grants and medicines from Pfizer and The Pfizer Foundation to help combat the global health effects of the COVID-19 pandemic
31.1 million
Donated more than 31.1 million doses of Zithromax to 12 countries bringing our cumulative donation to more than 925 million doses since 1998
$2.5 million
Provided $2.5 million in charitable funding to 10 organizations in the U.S. working to improve health outcomes and reduce disparities in equitable care for African-American communities
2020 Patients Impact
(Patient counts are estimates derived from multiple data sources; results exclude Upjohn)
~86 million
~4.4 million
~58 million
~80 million
~2.5 million
~28 million
people were treated with anti-infectives
~12,400
patients were treated for rare diseases
~1 million
2020 global footprint
(as of December 31, 2020)
~78,500
employees
43
manufacturing sites (Algiers site transfer to Viatris delayed until H1 2021)
> 125
2020 Pipeline Advancements
(BNT162b2, which is based on BioNTech’s proprietary mRNA technology, was developed by both BioNTech and Pfizer, and the marketing authorization holder is BioNTech in the United States, Europe, U.K., Canada, and other countries.
)
7
product approvals (2 key approvals, 5 second market approvals)
7
>50
Emergency Use Authorizations/Conditional Authorizations/Temporary Authorizations for the Pfizer-BioNTech COVID-19 vaccine, BNT162b2
32
pipeline assets advanced
Creating shareholder value in 2020
$41.9 billion
$8.4 billion
returned to shareholders through cash dividends
$9.4 billion
invested in research & development
Being a Responsible Corporate Citizen
in 2020
(The Pfizer Foundation is a charitable organization established by Pfizer Inc. It is a separate legal entity from Pfizer Inc. with distinct legal restrictions.)
$40 million
Committed $40 million in medical and charitable cash grants and medicines from Pfizer and The Pfizer Foundation to help combat the global health effects of the COVID-19 pandemic
31 million
Donated more than 31.1 million doses of Zithromax to 12 countries bringing our cumulative donation to more than 925 million doses since 1998
$2.5 million
Provided $2.5 million in charitable funding to 10 organizations in the U.S. working to improve health outcomes and reduce disparities in equitable care for African-American communities
skip
Market Context
Understanding the External Environment
Pfizer aimed high in 2020, with patient-centric goals that would spur the company toward positive change and influence the biopharmaceutical industry to follow suit. In a year when the global health care ecosystem was dramatically impacted by COVID-19, Pfizer remained steadfast in its commitment to pursuing breakthrough science, addressing structural challenges and alleviating patient barriers to innovative medicines.
Market Context